2016, Number 3
<< Back Next >>
Sal Jal 2016; 3 (3)
Vacunas en estudios clínicos para combatir la tuberculosis
Llamas-González YY, Marino-Marmolejo EN, Flores-Valdez MA
Language: Spanish
References: 17
Page: 167-171
PDF size: 230.39 Kb.
ABSTRACT
Tuberculosis (TB) is a global health problem, being
the leading cause of death among millions of people
each year, mainly because of comorbidity with human
immunodeficiency (HIV) virus. This paper is intended
to address the progress that currently exists with regard
to the development of vaccines against tuberculosis.
We know today that TB is one of the most difficult
to control infectious diseases, therefore, the search to
develop a universal vaccine that is protective against
tuberculosis still continues. So far, there are nearly 20
vaccine candidates being evaluated at different stages
of preclinical and clinical trials. These clinical trials
aim to identify a tuberculosis vaccine that is safe, more
effective than BCG, which is widely applicable and
contributes to control of the disease. At present, the
field of study has focused on the selection of antigens
that induce a better activation of immune response
and thus stimulate cells that are able to produce proinflammatory
cytokines; also, on the other hand,
manipulation of the components of the lining of the
lung can play an important role in the protective
immune response to infection by
Mycobacterium
tuberculosis. Within the recent perspectives there is
the urgent need of a highly effective vaccine against
pulmonary TB.
REFERENCES
1 Andersen P, Urdahl KB. Tb Vaccines; Promoting Rapid and Durable Protection in the Lung, Curr Opin Immunol, 35 (2015), 55-62.
2 Bricks LF, [Percutaneous or Intradermal Bcg Vaccine?], J Pediatr (Rio J), 80 (2004), 93-8. 3 Dagg B, Hockley J, Rigsby P, Ho MM. Th e Establish ment of Sub- Strain Specifi c Who Reference Reagents for Bcg Vaccine, Vaccine, 32 (2014), 6390-5.
4 Ellis RD, Hatherill M, Tait D , Snowden M, Churchyard G, Hanekom H, et al. Innovative Clinical Trial Designs to Rationalize Tb Vaccine Development, Tuberculosis (Edinb), 95 (2015), 352-7.
5 Ernst JD. Th e Immunological Life Cycle of Tuberculosis, Nat Rev Immunol, 12 (201 2), 581-91.
6 Fine PE, Variation in Protection by Bcg: Implications of and for Heterologous Immunity, Lancet, 346 (1995), 1339-45.
7 Geldenhuys H, Mearns H, Miles DJ, Tameris M, Hokey D, Sh i Z, et al. Trial Study Groupa, ‘Th e Tuberculosis Vaccine H4:Ic31 Is Safe and Induces a Persis tent Polyfunctional Cd4 T Cell Response in South African Adults: A Randomized Controlled Trial’, Vaccine, 33 (2015), 35 92-9.
8 Sismanidis-Glaziou P, Floyd C, Raviglione K, Glaziou M, Sismanidis C, Floyd K, et al. Cold Spring Harb Perspect Med, 5:a017798 (2015).
9 Hussey GD, Watkins ML, Goddard EA, Gottschalk S, Hughes EJ, Iloni K, et al. Neonatal Mycobacterial Specifi c Cytotoxic T-Lymphocyte a nd Cytokine Profi les in Response to Distinct Bcg Vaccination Strategies. Immunology, 105 (2002), 314-24.
10 Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, et al. Progress in Tuberculosis Vaccine Development and Host- Directed Th erapies--a State of the Art Review, Lancet Respir Med, 2 (2014), 301-20.
11 Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, et al. First-in-Human Trial of the Post-Exposure Tuberculosis Vaccine H56:Ic31 in Mycobacterium Tuberculosis Infected and Non- Infected Healthy Adults, Vaccine, 33 (2015), 4130-40.
12 Moliva JI, Turner J, Torrelles JB. Prospects in Mycobacterium Bovis Bacille Calmette Et Guerin (Bcg) Vaccine Diversity and Delivery: Why Does Bcg Fail to Protect against Tuberculosis?, Vaccine, 33 (2015), 5035-41.
13 Penn-Nicholson A, Geldenhuys H, Burny W, van der Mo st R, Day CL, Jongert E, et al. Safety and Immunogenicity of Candidate Vaccine M72/As01e in Adolescents in a Tb Endemic Setting, Vaccine, 33 (2015), 4025-34.
14 Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. Infl uence of Bcg Vaccine Strain on the Immune Response and Protection against Tuberculosis, FEMS Microbiol Rev, 32 (2008), 821-41.
15 Schepers K, Dirix V, Mouchet F, Verscheure V, Lecher S, Locht C, Mascart F. Early Cellular Immune Response to a New Candidate Mycobacterial Vaccine Antigen in Childhood Tuberculosis, Vaccine, 33 (2015), 1077-83.
16 Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowde n MA, Lockhart S, et al. Trial Study Team, Safety and Effi cacy of Mva85a, a New Tuberculosis Vaccine, in Infants Previously Vaccinated with Bcg: A Randomised, Placebo-Controlled Phase 2b Trial, Lancet, 381 (2013), 1 021-8.
17 Wang Z, Zhang J, Liang J, Zhang Y, Teng X, Yuan X et al. Protection against Mycobacterium Tuberculosis Infection Off ered by a New Multistage Subunit Vaccine Correlates with Increased Number of Ifn-Gamma+ Il-2+ Cd4+ and Ifn-Gamma+ Cd8+ T Cells, PLoS One, 10 (2015), e01 22560.
18 WHO, ‘Who Tuberculosis Fact Sheet 2015,’ 2015) [Accessed March 20th.
Full text